MELBOURNE, Australia--(BUSINESS WIRE)--Anadis Limited (ASX:ANX; OTC: ANDIY), today announced major progress in its anti-flu virus antibody program. The milk- derived anti-flu virus antibodies are all-natural and will provide immediate-acting immune enhancement once deposited topically on mucosal surfaces that come in contact with the influenza virus. Results from human trials are anticipated within 18 months. Addressing both seasonal and avian influenza (bird flu) virus strains, Anadis plans to introduce products using these antibodies (Flubodies) into the market within 2-3 years. This decision follows several successful animal trials with mice, conducted by Anadis and an internationally-recognized influenza research group at the University of Melbourne led by Professor Lorena Brown, using recognized pathways for development of anti-avian flu virus treatments. The dairy derived anti-flu virus antibody significantly decreased disease mortality and were significantly interrupting the disease process after challenges with lethal doses of virus. Anadis prototype milk-derived hyperimmune antibody preparation ("flubody") improved the survival rate of infected mice (exposed to lethal flu) from 0% in non-treated mice to up to 60% in treated mice. In other trials, it was shown that the progress of disease could be delayed for days with a single application of the prototype formulation.
